These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. Greiser M; Neuberger HR; Harks E; El-Armouche A; Boknik P; de Haan S; Verheyen F; Verheule S; Schmitz W; Ravens U; Nattel S; Allessie MA; Dobrev D; Schotten U J Mol Cell Cardiol; 2009 Mar; 46(3):385-94. PubMed ID: 19100271 [TBL] [Abstract][Full Text] [Related]
8. [Remodelling in atrial fibrillation]. Lévy S; Sbragia P Arch Mal Coeur Vaiss; 2005 Apr; 98(4):308-12. PubMed ID: 15881846 [TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation begets atrial fibrillation in the pulmonary veins on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans. Rostock T; Steven D; Lutomsky B; Servatius H; Drewitz I; Klemm H; Müllerleile K; Ventura R; Meinertz T; Willems S J Am Coll Cardiol; 2008 Jun; 51(22):2153-60. PubMed ID: 18510963 [TBL] [Abstract][Full Text] [Related]
10. Molecular basis of electrical remodeling in atrial fibrillation. Van Wagoner DR; Nerbonne JM J Mol Cell Cardiol; 2000 Jun; 32(6):1101-17. PubMed ID: 10888261 [TBL] [Abstract][Full Text] [Related]
11. [The electrocardiology of atrial fibrillation]. Costantini M; Crema A Ital Heart J Suppl; 2000 May; 1(5):632-40. PubMed ID: 10834128 [TBL] [Abstract][Full Text] [Related]
13. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of atrial remodeling and clinical relevance. Nattel S; Shiroshita-Takeshita A; Cardin S; Pelletier P Curr Opin Cardiol; 2005 Jan; 20(1):21-5. PubMed ID: 15596955 [TBL] [Abstract][Full Text] [Related]
15. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part II: New insights into the electrophysiological mechanisms of atrial fibrillation termination. Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M Ital Heart J; 2003 Jul; 4(7):442-7. PubMed ID: 14558294 [TBL] [Abstract][Full Text] [Related]
16. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. Burstein B; Nattel S J Am Coll Cardiol; 2008 Feb; 51(8):802-9. PubMed ID: 18294563 [TBL] [Abstract][Full Text] [Related]
17. Clinical assessment of antiarrhythmic agents for paroxysmal atrial fibrillation guided by modification of electrophysiologic arrhythmogenicity. Sasano T; Okishige K; Azegami K; Isobe M J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1250-7. PubMed ID: 15574173 [TBL] [Abstract][Full Text] [Related]
18. Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence? Nattel S J Cardiovasc Electrophysiol; 2004 Aug; 15(8):885-6. PubMed ID: 15333079 [No Abstract] [Full Text] [Related]
19. Atrial fibrillation in heart failure: steady progress but still a long way to go. Stambler BS; Laurita KR Circ Arrhythm Electrophysiol; 2008 Jun; 1(2):77-9. PubMed ID: 19808396 [No Abstract] [Full Text] [Related]
20. [Molecular basis of remodelling in atrial fibrillation]. Dobrev D Dtsch Med Wochenschr; 2004 Apr; 129(15):827-30. PubMed ID: 15054689 [No Abstract] [Full Text] [Related] [Next] [New Search]